Our Mission

We’re on a mission to revolutionize disease screening through noninvasive urine spectroscopy and artificial intelligence

Our Values

Accuracy

Strive for the highest level of accuracy and precision to ensure reliable results for patients and healthcare providers

Compassion

Show empathy and compassion for individuals undergoing screening, recognizing the sensitivity and anxiety associated with medical tests

Innovation

Foster a culture of continuous innovation, always seeking new and improved methods to enhance the accuracy and convenience of diagnostics

Integrity

Uphold the highest ethical standards in all interactions, from data privacy and patient confidentiality to business practices and research

Patient First

Prioritize the well-being, comfort, and convenience of patients, ensuring that their needs are at the forefront of all decision-making processes

Scientific Rigor

Commit to rigorous scientific methodologies, including peer-reviewed research, clinical trials, and validation studies, to ensure the reliability of diagnostic methods

Leadership

Matthew Laskowski, MSc

Matthew Laskowski, MSc

Chief Executive Officer

Technology expert with +6 years of Strategy & Operations experience

Launched GTMs for +10 products in FinTech and SaaS

Leader at 2 high-growth tech companies

Linkedin
Dragan Sebišanović, MBT

Dragan Sebišanović, MBT

Chief Scientific Officer

Biotech veteran of +20 years with +15 years in diagnostic startups

Launched 3 diagnostic products from concept to commercialization

Leader at 5 diagnostic companies with 3 successful exits

Linkedin

The Story

Over time, Dragan became disillusioned with sequencing and was in search of an alternative technology. After a +5-year diagnostic journey for an uncommon autoimmune disease, Matthew discovered an alternative data-driven approach that he would have liked to use for himself. Together, we discovered that these two puzzle pieces (Dragan’s problem and Matthew’s solution) fit together perfectly and that we shared the same goal. We named our company Toby, after Sherlock Holmes's bloodhound.

Team

Travis Gerke, ScD

Travis Gerke, ScD

Head of Data Science

Harvard trained bioinformatician with +15 years in prostate cancer data science and experienced in FDA engagement

Hubert Fenton, MD

Hubert Fenton, MD

Medical Director

Johns Hopkins trained physician with +20 years in healthcare and responsible for running our lab
Jackie Magno, MSM

Jackie Magno, MSM

Advisor

Operating Committee Chair and Managing Director for Golden Seeds Silicon Valley for +13 years

Wen-Yee Lee, Prof

Wen-Yee Lee, Prof

Advisor

Research in GC-MS for +20 years and VOCs for prostate cancer detection for +6 years

Collaborators

Duke Cancer Institute

Duke Cancer Institute

Collaborator

Collaborator for our Clinical Utility Study and Clinical Validation Study

University of Southern Alabama

University of Southern Alabama

Collaborator

Perfect demographic with interest in kidney, bladder, breast, lung, and stomach cancer

MassChallenge

MassChallenge

Highly Ranked Acccelerator

Chosen from +1,300 applicants for the highly ranked remote and equity-free accelerator

Be part of the movement for early detection via spectroscopy of urine and artificial intelligence

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.